SecBot SecBot

TARS

Tarsus Pharmaceuticals, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001819790 Biotech & Drug Discovery
$78.68 −1.60 (−1.99%)
Nov 16 4:00 PM ET · prev $80.28
Market cap
$3.8B
Mid cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$104.00
+32% · range $88.00–116.00
1 year
+6.1%
from $74.17 · Nov 17
30 days
+13.2%
from $69.50
52-week range
$56.11–90.78
−13% from high · low Jul 14
Avg volume 20D
871.0K
Nov 4 spike 2.55M
Short interest
6.07M
≈12.3% of shares · +5.8%
Days to cover
6.9
at average volume
Insider net
−$7.6M
0 buyers · 6 sellers · since Apr 24
New fund stakes
4
Q3 2026 13F · 1 exit
Filing reports
20
analyzed by SecBot
SecBot read MIXED 13 reports · 90 days
Balance 2 bearish · 1 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 9/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $7.6M.

  • InstitutionsBULLISH

    Q3 2026: 30 added (4 new), 19 trimmed or exited. Largest new: Aberdeen Group $39.7M, Marshall Wace $11.7M.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.044 → −$0.275 over 90 days.

  • Short sellersSTEADY

    Short interest +5.8% to 6.07M shares. 6.9 days to cover, ≈12.3% of shares.

  • TrendUPTREND

    5% above its 50-day average.

Who's buying

13F· Q3 2026
4
new positions
1
exit
$51.4M
in new stakes · top 2 shown
FundMoveSharesValue
FMR LLCDOUBLED3,273,307$250.4M
Assenagon Asset Management S.A.TRIM615,974$48.4M
Aberdeen Group plcNEW505,591$39.7M
UBS Group AGDOUBLED471,978$37.1M
WASATCH ADVISORS LPADD468,041$36.8M
Qube Research & Technologies LtdDOUBLED355,636$28.0M
BARCLAYS PLCDOUBLED261,801$20.6M
MARSHALL WACE, LLPNEW148,547$11.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy7Buy8Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +32%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 4, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 8, 2026Jefferies
MAINTAIN
MAINTAINBuy
Aug 12, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Jul 31, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Jul 21, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$7.6M
sold · 6 insiders
DateInsiderTypeValue
Nov 3, 2026
Clase Neera
Chief Commercial Officer
Nov 3, 2026
AWARD10,587 sh
Nov 3, 2026
Clase Neera
Chief Commercial Officer
Nov 3, 2026
AWARD6,678 sh
Sep 15, 2026
PYOTT DAVID E I
Director
Sep 15, 2026
EXERCISE201 sh
Sep 15, 2026
YARNO WENDY L
Director
Sep 15, 2026
EXERCISE302 sh
Sep 15, 2026
LINK WILLIAM J PHD
Director
Sep 15, 2026
SELL$914.5K
Sep 15, 2026
LINK WILLIAM J PHD
Director
Sep 15, 2026
SELL$5.3K
Sep 15, 2026
LINK WILLIAM J PHD
Director
Sep 15, 2026
EXERCISE201 sh
Sep 15, 2026
LINK WILLIAM J PHD
Director
Sep 15, 2026
SELL$60.0K

Earnings setup

Estimates
−$0.28
EPS estimate, this quarter
−525%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.28-$0.59–$0.14+91.9%$211.0M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
6,066,524
shares short
+5.8%
vs prior settlement
6.9
days to cover
≈12.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
CEO Bobak Azamian filed a Form 144 notice of intent to sell 10,000 shares of Tarsus Pharmaceuticals common stock, with…
144 · Impact 2/10
Nov 5, 2026 SEC
Neera Clase, the new Chief Commercial Officer of Tarsus Pharmaceuticals, filed a Form 3 initial statement of…
3 · Impact 2/10
Nov 5, 2026 Other
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed a Schedule 13G disclosing a 6.4% passive stake in Tarsus Pharmaceuticals as of September 30…
SC 13G · Impact 3/10
Nov 3, 2026 Insider
Clase Neera was granted 10,587 shares
Chief Commercial Officer
Nov 3, 2026 Insider
Clase Neera was granted 6,678 shares
Chief Commercial Officer
Sep 30, 2026 Inst.
FMR LLC · DOUBLED
3,273,307 shares ($250.4M)
Sep 30, 2026 Inst.
Assenagon Asset Management S.A. · TRIM
615,974 shares ($48.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 5, 2026
Press release
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the…
Nov 3, 2026
Earnings
Tarsus Reports Third Quarter 2026 Financial Results
Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year
Nov 3, 2026
Earnings result
TARS Q3 2026 Earnings: EPS $-0.78 (+72.0% vs est)
Oct 29, 2026
Earnings
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at…
Oct 28, 2026
Press release
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as…

SecBot reports

20 filings · 1 press release · 2 bullish · 3 bearish · 2 mixed · 13 neutral
All TARS filing & press-release reports (21)